Skip to main content

Ergomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program

Written by Customer Service on . Posted in Public Companies.

PRESS RELEASEErgomed’s PrimeVigilance Announces Provision of Clinical Safety Services for COVID-19 Clinical Trial Program
Guildford, UK – 30 March 2020: Ergomed plc (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, today announces that it will provide drug safety services through its specialist pharmacovigilance provider, PrimeVigilance, for an ongoing US clinical trial to assess the effect of a rheumatoid arthritis treatment on patients with severe COVID-19 infection.
Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: “COVID-19 represents a severe and pressing challenge for all involved in the development of new medicines and we are proud to be expanding our involvement in the field by bringing our expertise in drug safety and pharmacovigilance to this program. The rapid initiation of clinical trials and establishment of appropriate safety monitoring will be critical to providing new treatments which may improve outcomes for patients.”
ENDSEnquiries:About Ergomed plcErgomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.